No Data
Express News | Cue Biopharma Presents Positive Updated Data From Its Phase 1 Trials of Cue-101 and Cue-102 in Head and Neck Cancer and Wt1 Positive Cancers at the SITC 39TH Annual Meeting
Cue Biopharma (NASDAQ:CUE) Adds US$31m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 89%
12 Health Care Stocks Moving In Monday's Intraday Session
Trevena TRVN -58% AH NASDAQ Delisting; Cue Biopharma CUE +42% SITC Presentation
Express News | Cue Biopharma Inc: Second Amendment Removes Requirement for Co to Maintain in Accounts of Svb Cash Equal to at Least $20 Mln
Express News | Cue Biopharma Inc: Enters Second Amendment to Loan Agreement With Svb
No Data
No Data